generated from naïve, canine germline genes, don't require costly, time-consuming caninization and can be readily engineered into mAbs, BiTEs or CAR-T therapies. As a result, our therapies are designed for precision efficacy and lack of immunogenicity, not possible with other discovery technologies. Vetigenics is advancing three internally developed antibody products into the clinic with our 1st in dog studies starting during 1Q21